• Fever

  Participated · Series B · Nov 2015

  Fever is a New York City-based live entertainment discovery platform with strong Spanish roots. The company curates and sells tickets for immersive and branded experiences, including Harry Potter, Stranger Things, Van Gogh, Jurassic World, Friends, and the Candlelight classical concert series. Via Candlelight, Fever has become the largest seller of live classical music in the world. Over the last year the company says it doubled its turnover and that North America now comprises over 50% of group revenues. Just over a year after a Series E that raised over $227 million at a valuation above $1 billion, Fever secured a new financing valuing it at about $1.8 billion. The new funding is aimed at doubling down on existing efforts and investing in new content opportunities. Fever is a live-entertainment discovery platform that analyses consumer data to help creators curate unique events and experiences. The platform helped organizers adapt during and after COVID by making experiences more accessible to new audiences worldwide. Fever cites revenue growth of 10x since 2019. Management and investors point to its technology, partnerships, and creator network as the basis for continued growth and expansion. The company emphasizes enabling memorable real-life (IRL) experiences despite the rise of digital ‘metaverse’ propositions. Fever was founded in 2011 by Pep Gomez and is now co-led by Ignacio Bachiller Ströhlein, Alexandre Perez Casares, and Francisco Hein. Fever’s core product is a consumer app that generates personalized event listings and feeds into its Secret Media Network, which collects anonymized user data from the company’s social media channel. That anonymized data is analyzed by Fever’s proprietary algorithms to help companies plan and create events, with examples including themed shows in Hollywood and Los Angeles and Candlelight Concerts aimed at young audiences. The company claims 25 million unique users per month across main markets in London, New York, Paris and Madrid. Fever says it differentiates from other platforms by avoiding discount-driven events and by using firsthand behavioral data to predict demand for new experiences. The startup plans to use the new funding to expand into new cities, targeting Chicago and Barcelona next and then launching new markets every couple of months, mostly in the U.S. and Europe this year and Asia next year. Fever may also collaborate with other Rakuten portfolio companies to help SMBs increase customer engagement. Fever operates an urban events discovery app alongside a branded media network (Secret Media Network and city channels such as Secret London and Secret NYC) to market events and gather community insights. It uses anonymised behavioral data and recommendation algorithms to predict untapped demand and A/B-test themed 'Fever Originals' immersive experiences across venues and cities. The company says its network reaches more than 12M unique users per week in its main markets (London, New York, Paris, Madrid), enabling large waitlists and rapid sell-outs. Fever runs a 'marketing fee' monetization strategy—no booking fees for users—charging organisers commissions tied to its ability to drive ticket sales, which it says is roughly 3–5× a traditional ticketing fee. The business reached break-even about a year ago and reports its current cities have been growing self-sufficiently at roughly 100% year‑on‑year since then. Fever plans to expand its own-brand events and enter new markets across Europe and North America. Fever was founded in June 2011 by Pep Gómez under the corporate name Kzemos Technologies, S.L. The company is listed with locality Barcelona and opened an office in New York in 2012. Fever has raised multiple rounds since 2012, including a 2012 seed via a €1M convertible, further €1M in 2013, $3M in 2014 and larger financings in 2015. In 2015 it reported €6.6M in revenue (five times 2014) and a net profit of €105,000, and the company had about 80 employees. Fever has stated plans to reach profitability for all its markets within a maximum of two months.

• Prosonix

  Participated · Series B · May 2012

  Prosonix is a specialty pharmaceutical company based in Oxford, UK, led by CEO David Hipkiss. It develops a portfolio of inhaled respiratory medicines by reformulating known and approved drugs using its own particle engineering technology. Its lead products include PSX1001, a generic drug for asthma, and PSX1002 for chronic obstructive pulmonary disease. The company is also advancing development of next‑generation combination respiratory medicines. Prosonix intends to use financing proceeds to advance its proprietary product pipeline of therapies. Prosonix Ltd. is an Oxford, UK-based developer of high-value respiratory therapies enabled by its novel and proprietary particle engineering technology. The company's patented particle engineering technology provides an opportunity to develop novel and generic mono and combination respiratory medicines efficiently in a range of affordable and commercially available Metered Dose and Dry Powder Inhalers. Prosonix has commercialized its technology via partnering with a range of originator, specialty, device and generic pharma companies. It intends to use the £11.4m financing to advance its emerging proprietary product pipeline of mono and multi-component combination therapies and to support Phase 2 clinical trials as required. Founded in early 2006, Prosonix combines proprietary development with partner-led commercialization strategies. In conjunction with the financing, Edwin de Graaf from Gilde Healthcare Partners and Karl Nägler from Ventech will join Prosonix’s Board of Directors.

• Xceleron Inc.

  Participated · Equity · Feb 2012

  Xceleron provides bioanalytical Accelerator Mass Spectrometry (AMS) services to accelerate early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. Led by CEO Michael Butler and Vice President Analytical Operations Stuart Best, Xceleron supports accelerated early drug development through these analyses. Founded in 1997 in York, UK, the company opened its US facility in Maryland in 2008. It plans to use the new funding to consolidate operations in Germantown, MD, relocate senior analytical staff from York, and hire new staff in Maryland while retaining a study design and project management presence in the UK. Xceleron recently raised $2.4M with backing from existing investors Albion Ventures and Solon Ventures. Xceleron provides human data and insights to drug developers to support early and well‑informed portfolio decisions and preclinical evaluation of proteins and other high molecular weight drugs. The company supplies reliable information about drug candidates across multiple clinical settings. Xceleron realized significant revenue growth in 2009 and now partners with most of the top 20 pharmaceutical companies. It supports clients by delivering important data earlier in clinical studies than was previously possible. Xceleron is based in York, UK and Germantown, MD. The company plans to use new funding to accelerate future growth and expand capacity in line with customer demand.

No current team members are available.